Rocket Pharmaceuticals, Inc. (RCKT) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value -101.29×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | -101.29× | Operating income ÷ reported interest expense. $-191.64M ÷ $1.89M ≈ -101.29× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 124.37M USD | Research and Development Expense |
| Revenue | 0.00 USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 31.78M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -191.64M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 1.89M USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $124.37M | $0.00 | $31.78M | $-191.64M | $1.89M | (m) | (m) | -101.29× | Reported |
| 2026-03-31 | $137.53M | $0.00 | $35.22M | $-215.87M | $1.89M | (m) | (m) | -114.10× | Reported |
| 2025-12-31 | $142.01M | $0.00 | $37.06M | $-231.75M | $1.89M | (m) | (m) | -122.55× | Reported |
| 2025-09-30 | $150.03M | $0.00 | $42.03M | $-250.48M | $1.89M | (m) | (m) | -132.46× | Reported |
| 2025-06-30 | $158.27M | $0.00 | $43.52M | $-267.65M | $1.89M | (m) | (m) | -141.69× | Reported |
| 2025-03-31 | $161.96M | $0.00 | $44.00M | $-270.22M | $1.89M | (m) | (m) | -143.20× | Reported |
| 2024-12-31 | $171.24M | $0.00 | $43.92M | $-273.20M | $1.89M | (m) | (m) | -144.86× | Reported |
| 2024-09-30 | $175.63M | $0.00 | $42.76M | $-273.79M | $1.88M | (m) | (m) | -145.40× | Reported |
| 2024-06-30 | $180.16M | $0.00 | $41.83M | $-269.80M | $1.88M | (m) | (m) | -143.43× | Reported |
| 2024-03-31 | $185.20M | $0.00 | $40.74M | $-264.84M | $1.88M | (m) | (m) | -141.02× | Reported |
| 2023-12-31 | $186.34M | $0.00 | $39.41M | $-259.66M | $1.88M | (m) | (m) | -138.48× | Reported |
| 2023-09-30 | $194.63M | $0.00 | $39.17M | $-265.46M | $1.87M | (m) | (m) | -141.81× | Reported |
| 2023-06-30 | $191.17M | $0.00 | $36.53M | $-258.52M | $1.87M | (m) | (m) | -138.25× | Reported |
| 2023-03-31 | $181.15M | $0.00 | $33.65M | $-243.97M | $1.87M | (m) | (m) | -130.75× | Reported |
| 2022-12-31 | $165.57M | $0.00 | $31.01M | $-224.34M | $1.86M | (m) | (m) | -120.48× | Reported |
| 2022-09-30 | $148.55M | $0.00 | $28.35M | $-199.59M | $1.86M | (m) | (m) | -107.42× | Reported |
| 2022-06-30 | $144.79M | $0.00 | $27.66M | $-190.75M | $1.93M | (m) | (m) | -99.09× | Reported |
| 2022-03-31 | $127.96M | $0.00 | $27.61M | $-170.59M | $1.71M | (m) | (m) | -99.64× | Reported |
| 2021-12-31 | $125.48M | $0.00 | $29.24M | $-167.25M | $2.98M | (m) | (m) | -56.18× | Reported |
| 2021-09-30 | $144.35M | $0.00 | $28.27M | $-182.15M | $4.16M | (m) | (m) | -43.84× | Reported |
| 2021-06-30 | $126.03M | $0.00 | $25.33M | $-159.90M | $5.59M | (m) | (m) | -28.62× | Reported |
| 2021-03-31 | $117.97M | $0.00 | $22.51M | $-149.41M | $7.12M | (m) | (m) | -20.98× | Reported |
| 2020-12-31 | $106.38M | $0.00 | $18.57M | $-134.30M | $6.97M | (m) | (m) | -19.28× | Reported |
| 2020-09-30 | $70.01M | $0.00 | $15.86M | $-94.71M | $6.67M | (m) | (m) | -14.20× | Reported |
| 2020-06-30 | $63.18M | $0.00 | $14.50M | $-86.49M | $6.17M | (m) | (m) | -14.02× | Reported |
| 2020-03-31 | $60.44M | $0.00 | $14.15M | $-81.33M | $5.93M | (m) | (m) | -13.72× | Reported |
| 2019-12-31 | $58.62M | $0.00 | $13.37M | $-76.15M | $5.96M | (m) | (m) | -12.78× | Reported |
| 2019-09-30 | $67.64M | $0.00 | $12.83M | $-83.05M | $6.64M | (m) | (m) | -12.50× | Reported |
| 2019-06-30 | $65.87M | $0.00 | $12.75M | $-79.22M | $6.35M | (m) | (m) | -12.47× | Reported |
| 2019-03-31 | $62.66M | $0.00 | $11.40M | $-75.70M | $6.22M | (m) | (m) | -12.18× | Reported |
| 2018-12-31 | $53.27M | $0.00 | $13.60M | $-71.16M | $6.04M | (m) | (m) | -11.78× | Reported |
| 2018-09-30 | $33.78M | (m) | $13.85M | $-58.23M | $7.59M | (m) | (m) | -7.67× | Reported |
| 2018-06-30 | $25.61M | (m) | $11.94M | $-49.62M | $6.41M | (m) | (m) | -7.74× | Reported |
| 2018-03-31 | $17.65M | (m) | $9.32M | $-38.27M | $5.01M | (m) | (m) | -7.65× | Reported |
| 2017-12-31 | $14.19M | (m) | $4.04M | $-26.74M | $3.58M | (m) | (m) | -7.47× | Reported |
| 2017-09-30 | $23.03M | (m) | $3.42M | $-34.77M | $3.56M | (m) | (m) | -9.77× | Reported |
| 2017-06-30 | $28.63M | (m) | $3.31M | $-38.78M | $3.18M | (m) | (m) | -12.18× | Reported |
| 2017-03-31 | $31.47M | (m) | $3.21M | $-41.71M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $31.98M | (m) | $2.91M | $-41.88M | $1.42M | (m) | (m) | -29.53× | Reported |
| 2016-09-30 | $28.41M | (m) | $2.43M | $-37.87M | $525.00K | (m) | (m) | -72.13× | Reported |
| 2016-06-30 | $23.61M | (m) | $2.00M | $-32.58M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $19.10M | (m) | $1.50M | $-27.48M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $12.55M | (m) | $2.38M | $-20.40M | $1.23M | (m) | (m) | -16.58× | Reported |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $5.59M | (m) | $177.00K | $-7.70M | $980.00K | (m) | (m) | -7.86× | Reported |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |